America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
The President’s tariff increase comes at a critical moment, reflecting a clear understanding of the ongoing threats faced by the U.S. aluminum and steel industry, particularly from heavily subsidized foreign competitors.
Yes, reshoring manufacturing is possible. Investors will even go along for the ride, Guardian Bikes CEO Brian Riley told the Senate Small Business Committee in a hearing on May 14.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
CPA’s submission documents how the domestic trucking sector underpins U.S. commerce, and that ensuring a domestic industrial base for producing these trucks is vital to military readiness and civil emergency response.
As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.
While CPA recognizes certain positive elements of the deal — including a historic pivot towards prioritizing tariff revenue as well as industrial protection — it remains concerned about dangerous precedents being set by sacrificing domestic production while pursuing foreign market access.
By maintaining the 10% baseline tariff and capping UK auto imports at 100,000 vehicles per year before higher tariffs apply, the administration is demonstrating that trade policy can and should be used to protect and rebuild domestic industry.
President Trump’s Executive Order is a bold, necessary move to rebuild America’s pharmaceutical industry and protect our citizens.
President Trump’s action to close the de minimis loophole for China is a monumental victory for American workers, manufacturers, and national security.
